CN117597327A - 药物制剂 - Google Patents

药物制剂 Download PDF

Info

Publication number
CN117597327A
CN117597327A CN202080088987.0A CN202080088987A CN117597327A CN 117597327 A CN117597327 A CN 117597327A CN 202080088987 A CN202080088987 A CN 202080088987A CN 117597327 A CN117597327 A CN 117597327A
Authority
CN
China
Prior art keywords
compound
μιη
particle size
size distribution
niclosamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080088987.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·D·格利克
A·W·小奥皮帕里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entero Therapeutics Inc
Original Assignee
First Wave Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Wave Biopharma Inc filed Critical First Wave Biopharma Inc
Publication of CN117597327A publication Critical patent/CN117597327A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080088987.0A 2019-10-18 2020-10-16 药物制剂 Pending CN117597327A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923290P 2019-10-18 2019-10-18
US62/923,290 2019-10-18
PCT/US2020/056027 WO2021076922A1 (en) 2019-10-18 2020-10-16 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CN117597327A true CN117597327A (zh) 2024-02-23

Family

ID=75492817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080088987.0A Pending CN117597327A (zh) 2019-10-18 2020-10-16 药物制剂

Country Status (9)

Country Link
US (1) US20210114973A1 (https=)
EP (1) EP4045480A4 (https=)
JP (1) JP2022553934A (https=)
KR (1) KR20240039083A (https=)
CN (1) CN117597327A (https=)
AR (1) AR122323A1 (https=)
CA (1) CA3157861A1 (https=)
TW (1) TW202128610A (https=)
WO (1) WO2021076922A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118649135A (zh) * 2024-07-18 2024-09-17 广东药科大学 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法
CN119431243A (zh) * 2025-01-09 2025-02-14 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用
CN119841970A (zh) * 2025-01-23 2025-04-18 集美大学 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用
CN121406752A (zh) * 2025-12-26 2026-01-27 圣湘生物科技股份有限公司 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338783B1 (en) 2014-09-12 2024-01-24 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2021174024A1 (en) * 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN113768937B (zh) * 2021-11-15 2022-04-08 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease
CN117357523A (zh) * 2023-10-25 2024-01-09 澳门大学 利拉萘酯在制备预防和治疗肺纤维化药物中的用途
CN117466786A (zh) * 2023-12-25 2024-01-30 湖南一格制药有限公司 盐酸戊乙奎醚杂质及其制备方法
WO2025207484A1 (en) * 2024-03-25 2025-10-02 Merveille.Ai Use of aprepitant and cyclic dipeptide for weight control
CN119525016B (zh) * 2024-12-24 2026-04-07 中国矿业大学 一种组合捕收剂及其在钾长石反浮选脱硅中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626506A (zh) * 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) * 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
CN1546919A (zh) * 2003-07-13 2004-11-17 叶声羽 桑拿浴房
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN103751854B (zh) * 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
PE20181295A1 (es) * 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
EP3168211A1 (en) * 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626506A (zh) * 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Certificate of Analysis", MP BIOMEDICALS, 1 September 2012 (2012-09-01), pages 1 *
JIAN-RONG DAI等: "A novel molluscicidal formulation of niclosamide", PARASITOL RES, vol. 103, 31 December 2008 (2008-12-31), pages 405 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118649135A (zh) * 2024-07-18 2024-09-17 广东药科大学 一种缓解高尿酸血症肾病进程的药物制剂及其制备方法
CN119431243A (zh) * 2025-01-09 2025-02-14 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用
CN119841970A (zh) * 2025-01-23 2025-04-18 集美大学 一种具有抗炎活性的乙酰化卡拉胶及其制备方法和应用
CN121406752A (zh) * 2025-12-26 2026-01-27 圣湘生物科技股份有限公司 粘性生物样本的液化组合产品、核酸检测试剂盒及其应用

Also Published As

Publication number Publication date
TW202128610A (zh) 2021-08-01
AR122323A1 (es) 2022-08-31
CA3157861A1 (en) 2021-04-22
WO2021076922A1 (en) 2021-04-22
EP4045480A4 (en) 2023-11-22
EP4045480A1 (en) 2022-08-24
KR20240039083A (ko) 2024-03-26
US20210114973A1 (en) 2021-04-22
JP2022553934A (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
CN117597327A (zh) 药物制剂
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
JP7745892B2 (ja) Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
US10844080B2 (en) Compositions and methods for inhibiting arginase activity
US12054501B2 (en) Compositions and methods for inhibiting arginase activity
ES2820827T3 (es) Formas sólidas de un compuesto modulador de quinasas
JP2025081607A (ja) 統合的ストレス経路のプロドラッグ調節剤
US20180265523A1 (en) Antibacterial therapeutics and prophylactics
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
US20230102999A1 (en) Deuterated niclosamide
JP2009040767A5 (https=)
EP3866773A1 (en) Carbon monoxide prodrugs for the treatment of medical disorders
RU2824500C2 (ru) Пролекарственные модуляторы интегрированного пути стресса
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20240223